Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (113) 113
male (58) 58
clinical neurology (57) 57
female (52) 52
adult (42) 42
magnetic resonance imaging (36) 36
animals (35) 35
multiple sclerosis (35) 35
middle aged (32) 32
brain - pathology (25) 25
index medicus (25) 25
neurosciences (22) 22
disability (16) 16
glatiramer acetate (16) 16
multiple sclerosis, relapsing-remitting - drug therapy (15) 15
aged (14) 14
adolescent (13) 13
time factors (13) 13
multiple sclerosis - diagnosis (12) 12
multiple sclerosis - pathology (12) 12
treatment outcome (12) 12
child (11) 11
disease (11) 11
disease progression (11) 11
double-blind method (11) 11
mice (11) 11
multiple sclerosis, relapsing-remitting - pathology (11) 11
neurology (11) 11
cricetinae (10) 10
mri (10) 10
research article (10) 10
antigens, viral - analysis (9) 9
article (9) 9
disability evaluation (9) 9
encephalitis - pathology (9) 9
multiple sclerosis - drug therapy (9) 9
peptides - therapeutic use (9) 9
rubella - immunology (9) 9
rubella virus - immunology (9) 9
abridged index medicus (8) 8
antibodies, viral - analysis (8) 8
brain (8) 8
cell biology (8) 8
double-blind (8) 8
encephalitis - immunology (8) 8
immunology (8) 8
magnetic resonance imaging - methods (8) 8
multiple sclerosis - physiopathology (8) 8
multiple-sclerosis (8) 8
reproducibility of results (8) 8
virus diseases (8) 8
cells, cultured (7) 7
encephalitis - etiology (7) 7
longitudinal studies (7) 7
pathology (7) 7
prognosis (7) 7
settore med/27 - neurochirurgia (7) 7
virus replication (7) 7
care and treatment (6) 6
clinical trials (6) 6
diagnosis (6) 6
fluorescent antibody technique (6) 6
follow-up studies (6) 6
health aspects (6) 6
immunosuppressive agents - therapeutic use (6) 6
medicine, general & internal (6) 6
microscopy, electron (6) 6
pregnancy (6) 6
rats (6) 6
relapse rate (6) 6
severity of illness index (6) 6
trial (6) 6
virology (6) 6
age factors (5) 5
antibody specificity (5) 5
atrophy (5) 5
biochemistry & molecular biology (5) 5
brain - immunology (5) 5
brain - microbiology (5) 5
child, preschool (5) 5
clinically isolated syndromes (5) 5
cytopathogenic effect, viral (5) 5
demyelination (5) 5
drug therapy (5) 5
gerontology (5) 5
inclusion bodies, viral (5) 5
interferon-beta - therapeutic use (5) 5
lesions (5) 5
lymphocytes (5) 5
magnetic resonance spectroscopy (5) 5
molecular weight (5) 5
monoclonal antibodies (5) 5
pilot trial (5) 5
prospective studies (5) 5
t-cells (5) 5
therapy (5) 5
viruses (5) 5
administration, oral (4) 4
african americans (4) 4
aging (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
by Montalban, Xavier and Hauser, Stephen L and Kappos, Ludwig and Arnold, Douglas L and Bar-Or, Amit and Comi, Giancarlo and de Seze, Jérôme and Giovannoni, Gavin and Hartung, Hans-Peter and Hemmer, Bernhard and Lublin, Fred and Rammohan, Kottil W and Selmaj, Krzysztof and Traboulsee, Anthony and Sauter, Annette and Masterman, Donna and Fontoura, Paulo and Belachew, Shibeshih and Garren, Hideki and Mairon, Nicole and Chin, Peter and Wolinsky, Jerry S and ORATORIO Clinical Investigators
The New England Journal of Medicine, ISSN 0028-4793, 01/2017, Volume 376, Issue 3, pp. 209 - 220
Patients with primary progressive MS who received the anti-CD20+ humanized antibody ocrelizumab were less likely to have clinical deterioration that was... 
CD20 | MULTICENTER TRIAL | DEMYELINATION | DOUBLE-BLIND | CANCER-RISK | ANTIBODY | PATHOLOGY | DAMAGE | MEDICINE, GENERAL & INTERNAL | Antibodies, Monoclonal, Humanized - adverse effects | Brain - diagnostic imaging | Antibodies, Monoclonal, Humanized - therapeutic use | Antigens, CD20 | Double-Blind Method | Multiple Sclerosis, Chronic Progressive - immunology | T-Lymphocytes | Humans | Middle Aged | Male | Disease Progression | Young Adult | Magnetic Resonance Imaging | B-Lymphocytes - immunology | Adolescent | Infusions, Intravenous - adverse effects | Intention to Treat Analysis | Lymphocyte Count | Adult | Female | Multiple Sclerosis, Chronic Progressive - drug therapy | Neuroimaging | Multiple sclerosis | Intravenous administration | Pathogenesis | Clinical trials | Patients | Placebo effect | Magnetic resonance imaging | Lymphocytes B | Lymphocytes | Immunotherapy | Immunopathogenesis | Monoclonal antibodies | CD20 antigen | Respiratory tract diseases | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Pathophysiology of multiple sclerosis and the place of teriflunomide
by Gold, R and Wolinsky, J. S
Acta Neurologica Scandinavica, ISSN 0001-6314, 08/2011, Volume 124, Issue 2, pp. 75 - 84
Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. 
Acta Neurol Scand: 2011: 124: 75–84.
© 2010 John Wiley & Sons A/S.... 
teriflunomide | immunomodulator | immunology | multiple sclerosis | relapsing/remitting | disease‐modifying therapies | Immunomodulator | Teriflunomide | Multiple sclerosis | Immunology | Relapsing/remitting | Disease-modifying therapies | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | SUSCEPTIBILITY | NATURAL-HISTORY | CLINICAL NEUROLOGY | PATHOGENESIS | disease-modifying therapies | MEDICAL PROGRESS | GENETICS | DISEASE | ANIMAL-MODELS | LEFLUNOMIDE | T-CELLS | Toluidines - therapeutic use | Anti-Inflammatory Agents - pharmacology | Humans | Crotonates - pharmacology | Toluidines - pharmacology | Clinical Trials as Topic | Multiple Sclerosis - classification | Multiple Sclerosis - physiopathology | Crotonates - therapeutic use | Models, Immunological | Animals | Anti-Inflammatory Agents - therapeutic use | Multiple Sclerosis - pathology | Pyrimidines | Biological response modifiers | T cells | Interferon beta | Gold | Animal models | Antiinflammatory agents | Preservation | Myelin | Central nervous system | Clinical trials | Inflammation | Lymphocytes T | Macrophages | beta -Interferon | Lymphocytes B | Magnetic resonance imaging | copolymer 1 | Oligodendrocytes | pyrimidines
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
by Hauser, Stephen L and Bar-Or, Amit and Comi, Giancarlo and Giovannoni, Gavin and Hartung, Hans-Peter and Hemmer, Bernhard and Lublin, Fred and Montalban, Xavier and Rammohan, Kottil W and Selmaj, Krzysztof and Traboulsee, Anthony and Wolinsky, Jerry S and Arnold, Douglas L and Klingelschmitt, Gaelle and Masterman, Donna and Fontoura, Paulo and Belachew, Shibeshih and Chin, Peter and Mairon, Nicole and Garren, Hideki and Kappos, Ludwig and OPERA I OPERA II Clinical and OPERA I and OPERA II Clinical Investigators
The New England Journal of Medicine, ISSN 0028-4793, 01/2017, Volume 376, Issue 3, pp. 221 - 234
In two trials involving patients with relapsing multiple sclerosis, the anti-CD20+ monoclonal antibody ocrelizumab was associated with lower annualized relapse... 
TRIAL | MEDICINE, GENERAL & INTERNAL | ANTIBODIES TARGETING CD20 | DEMYELINATION | RITUXIMAB | B-CELL DEPLETION | DISEASE | CANCER-RISK | DISABILITY | PATHOLOGY | PROSPECTS | Antibodies, Monoclonal, Humanized - adverse effects | Recurrence | Brain - diagnostic imaging | Antibodies, Monoclonal, Humanized - therapeutic use | Antigens, CD20 | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Male | Disease Progression | Interferon-beta - therapeutic use | Magnetic Resonance Imaging | B-Lymphocytes - immunology | Interferon-beta - adverse effects | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Infusions, Intravenous - adverse effects | Adult | Female | Immunologic Factors - adverse effects | Immunologic Factors - therapeutic use | Multiple sclerosis | Intravenous administration | Lymphocytes B | Lymphocytes | β-Interferon | Immunotherapy | Clinical trials | Monoclonal antibodies | CD20 antigen | Gadolinium | Cognition | Interferon
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
by Polman, C.H and Reingold, S.C and Banwell, B and Clanet, M and Cohen, J.A and Filippi, M and Fujihara, K and Havrdova, E and Hutchinson, M and Kappos, L and Lublin, F.D and Montalban, X and O'Connor, P and Sandberg-Wollheim, M and Thompson, A.J and Waubant, E and Weinshenker, B and Wolinsky, J.S and Lund University and Neurologi, Lund and Neurology, Lund and Lunds universitet
Annals of Neurology, ISSN 0364-5134, 2011, Volume 69, Issue 2, pp. 292 - 302
New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis. The use of imaging for demonstration of... 
RADIOLOGICALLY ISOLATED SYNDROME | SPINAL-CORD LESIONS | INTRACORTICAL LESIONS | DIFFERENTIAL-DIAGNOSIS | INVERSION-RECOVERY | NEUROMYELITIS-OPTICA | GENERAL NEUROLOGY PRACTICE | HIGH-FIELD MRI | CLINICALLY ISOLATED SYNDROMES | CORTICAL-LESIONS | NEUROSCIENCES | CLINICAL NEUROLOGY | Magnetic Resonance Imaging | Multiple Sclerosis - diagnosis | Early Diagnosis | Humans | Sensitivity and Specificity | Revisions | Multiple sclerosis | Older people | Rapid Communication | Neurologi | Clinical Medicine | Neurology | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Defining the clinical course of multiple sclerosis The 2013 revisions
by Lublin, F.D and Reingold, S.C and Cohen, J.A and Cutter, G.R and Sorensen, P.S and Thompson, A.J and Wolinsky, J.S and Balcer, L.J and Banwell, B and Barkhof, F and Bebo, B and Calabresi, P.A and Clanet, M and Comi, G and Fox, R.J and Freedman, M.S and Goodman, A.D and Inglese, M and Kappos, L and Kieseier, B.C and Lincoln, J.A and Lubetzki, C and Miller, A.E and Montalban, X and O'Connor, P.W and Petkau, J and Pozzilli, C and Rudick, R.A and Sormani, M.P and Stuve, O and Waubant, E and Polman, C.H
Neurology, ISSN 0028-3878, 2014, Volume 83, Issue 3, pp. 278 - 286
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of... 
PATHOGENESIS | RADIOLOGICALLY ISOLATED SYNDROME | DIAGNOSIS | CONVERSION | DISEASE | SPINAL-CORD | FOLLOW-UP | NATURAL-HISTORY | BRAIN MRI | CLINICAL NEUROLOGY | Multiple Sclerosis - physiopathology | Humans | Clinical Trials as Topic - standards | Societies, Medical - standards | Multiple Sclerosis - therapy | Consensus | Multiple Sclerosis - classification | Views & Reviews
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
by Confavreux, Christian, Prof and O'Connor, Paul, Prof and Comi, Giancarlo, Prof and Freedman, Mark S, Prof and Miller, Aaron E, Prof and Olsson, Tomas P, Prof and Wolinsky, Jerry S, Prof and Bagulho, Teresa, MD and Delhay, Jean-Luc, MD and Dukovic, Deborah, MS and Truffinet, Philippe, MD and Kappos, Ludwig, Prof and TOWER Trial Grp and TOWER Trial Group
Lancet Neurology, ISSN 1474-4422, 2014, Volume 13, Issue 3, pp. 247 - 256
Summary Background Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing or relapsing–remitting multiple sclerosis. We aimed... 
Neurology | BG-12 | OUTCOMES | EFFICACY | SAFETY | III TRIAL | CLINICAL NEUROLOGY | Double-Blind Method | Administration, Oral | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Male | Treatment Outcome | Multiple Sclerosis, Relapsing-Remitting - diagnosis | Toluidines - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - epidemiology | Adult | Female | Crotonates - administration & dosage | Clinical trials | Medical colleges | Multiple sclerosis | Care and treatment | Voice recognition | Patient safety | Disease | Drug therapy | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects
by Cohen, Jeffrey A, Prof and Reingold, Stephen C, PhD and Polman, Chris H, Prof and Wolinsky, Jerry S, Prof and Int Advisory Comm Clinical Trial and International Advisory Committee on Clinical Trials in Multiple Sclerosis
Lancet Neurology, ISSN 1474-4422, 2012, Volume 11, Issue 5, pp. 467 - 476
Summary Many of the available disability outcome measures used in clinical trials of multiple sclerosis are insensitive to change over time, inadequately... 
Neurology | COGNITIVE DYSFUNCTION | FUNCTIONAL COMPOSITE | SECONDARY PROGRESSIVE MS | NATALIZUMAB | RELIABILITY | IMPACT SCALE MSIS-29 | QUALITY-OF-LIFE | VALIDITY | CLINICAL NEUROLOGY | DISEASE-ACTIVITY | IMPAIRMENT | Disability Evaluation | Retina - drug effects | Multiple Sclerosis - diagnosis | Tomography, Optical Coherence | Humans | Disease Progression | Randomized Controlled Trials as Topic | Brain - drug effects | Magnetic Resonance Imaging | Activities of Daily Living - classification | Neurologic Examination | Biomarkers | Brain - pathology | Retina - pathology | Multiple Sclerosis - drug therapy | Measurement | Clinical trials | Multiple sclerosis | Data processing | biomarkers | Quality of life
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights